(S)-pindolol benzoate

Actimed Therapeutics is running Phase 2 PROACT for ACM-001.1, the purified (S)-enantiomer benzoate salt of the 1970s beta-blocker pindolol, in obese adults losing weight on semaglutide [1][2]. The commercial thesis: exploratory DXA analyses of GLP-1 weight-loss trials suggest roughly 20-40% of the mass patients drop is lean tissue rather than fat, which becomes a functional problem in older or sarcopenic patients where losing muscle drives falls, weakness, and decline [3]. Actimed's bet is that a cheap, oral, decades-old adrenergic modulator can preserve muscle without blunting fat loss, slotting into the fastest-growing chronic prescription market in medicine. PROACT is a 120-patient, three-arm study with two ACM-001.1 doses versus placebo on background semaglutide, currently recruiting [2]. This is not a novel target: beta-adrenergic pharmacology has 50+ years of clinical use. The novelty sits in the indication (GLP-1-induced sarcopenia has no approved therapies and no defined regulatory pathway) and in the chiral-switch formulation. Given 2025-2026 start, a realistic primary readout window is late 2027 to 2028.

Chiral-switch investigational asset for a novel indication. The parent racemate pindolol has been off-patent for decades as an antihypertensive (brand Visken, first approved 1970s). ACM-001.1 is the (S)-enantiomer benzoate salt, also called espindolol benzoate, developed by Actimed Therapeutics, a small UK-based private biotech. The Phase 2 PROACT trial (NCT07101939) is recruiting, targeting 120 patients across two ACM-001.1 dose arms plus placebo on semaglutide background [2]. The listed sponsor is Actimed Therapeutics Ltd. No FDA breakthrough, fast track, or orphan designations have been disclosed. A Phase 1 comparative bioavailability study (NCT06028321, n=51) completed in healthy volunteers, comparing ACM-001.1 to standard pindolol [4]. PK data were published in the Journal of Cachexia, Sarcopenia and Muscle in 2025, establishing bioavailability and dose-linearity for the salt form [1]. No public timeline for PROACT primary completion or interim readout has been released; based on 120-patient enrollment starting in 2025-2026 with a typical 12-18 month accrual and 6-month treatment window, a plausible primary readout is late 2027 to 2028. IP position on the (S)-enantiomer and benzoate salt has not been publicly detailed in filings we can access; the racemate itself has no remaining composition-of-matter protection. Actimed has not disclosed a Phase 3 plan or a big-pharma partnering discussion in the public record.

Two beta-adrenergic receptors matter here. Beta-1 sits mostly on cardiac tissue and, when stimulated by catecholamines, increases heart rate, contractility, and catabolic energy expenditure. Beta-2 sits on skeletal muscle and, when stimulated, promotes muscle protein synthesis (which is why beta-2 agonists like clenbuterol get abused by bodybuilders) [5]. Espindolol is a beta-1 antagonist plus a beta-2 partial agonist, with additional 5-HT1a activity. The idea is to shut down sympathetic catabolic signaling while providing a low-level anabolic push through beta-2, without the tachycardia and arrhythmia risk of a full beta-2 agonist [1]. The validation anchor is quantifiable. Actimed's ACT-ONE Phase 2 in cancer cachexia (Coats et al. 2016, n=87 total, 42 high-dose / 14 low-dose / 31 placebo) reported that high-dose espindolol (10 mg BID) produced weight gain of +0.54 kg per 4 weeks versus a weight loss of -0.21 kg per 4 weeks on placebo in stage III/IV NSCLC and colorectal cancer patients [6]. Fat-free mass improved and fat mass was maintained, and handgrip strength was significantly improved on high-dose espindolol, one of the cleaner functional readouts in the cachexia literature at that time [6]. Beta-2 agonists demonstrably build muscle in humans and animals, but chronic use of full agonists causes tachycardia and arrhythmia risk. Mixed beta-1 antagonist plus partial beta-2 agonist pharmacology is a rational way to capture the anabolic upside without the cardiac downside. The translation from cancer cachexia to GLP-1-induced sarcopenia is a leap, since the two forms of muscle loss have different biology (inflammatory catabolism plus tumor-derived signals in cancer, versus caloric deficit and reduced protein intake with GLP-1s), but the anti-catabolic mechanism should apply in both.

PROACT is a Phase 2, randomized, placebo-controlled study enrolling 120 obese adults on semaglutide, with two ACM-001.1 dose arms plus placebo [2]. The primary endpoint is change in lean body mass, measured by DXA (dual-energy X-ray absorptiometry, the standard imaging scan for body composition). Sponsor is Actimed Therapeutics Ltd, status recruiting. Two protocol variants are described under one NCT: PROACT 1 during active semaglutide therapy, PROACT 2 in the post-semaglutide maintenance phase. Design gaps to note. First, 120 patients across three arms leaves roughly 40 per group, thin given DXA-measured LBM variance but appropriate for a proof-of-concept. Second, functional endpoints (grip strength, 6-minute walk test, short physical performance battery) do not appear as co-primaries in the public protocol summary. LBM on imaging is a mechanistic readout, not a clinical outcome. If regulators demand Phase 3 with functional endpoints or hard outcomes (falls, hospitalization in older obese patients), the development path lengthens considerably. Third, there is no stratification by age or baseline sarcopenia in the public protocol summary, even though the muscle-loss problem on GLP-1s is concentrated in older and lower-baseline-muscle populations. Fourth, the trial does not appear to be biomarker-selected, so any responder subgroup will be identified post hoc. Timing: with 2025-2026 recruitment start, 120-patient accrual over 12-18 months, and a treatment period likely in the 24-week range, primary data are plausibly late 2027 to 2028.

Our model estimates a 5% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 35%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk. LBM preservation on DXA is a mechanistic surrogate. Regulators may require functional endpoints in Phase 3, and any drug that preserves lean tissue mass without preserving strength or physical function has a payer problem downstream. A related worry on the fat-loss side: beta-1 antagonism reduces catecholamine-driven resting metabolic rate and thermogenesis, which could attenuate the caloric deficit semaglutide is prescribed to create. This is not a direct block of adipocyte lipolysis (adipose lipolysis in humans is driven by multiple beta subtypes, and the beta-2 partial agonism in espindolol could actually promote adipose lipolysis, partially offsetting the beta-1 effect). But if net fat loss is meaningfully blunted, physicians will not prescribe it. Safety risk. Bradycardia, fatigue, and exercise intolerance are on-target effects of any beta-blocker, and lowering resting heart rate in an already sedentary obese population is not free. Beta-2 partial agonism carries a theoretical cardiac arrhythmia signal from chronic beta-2 exposure data in COPD [8], though partial-agonist doses reduce that concern. Execution risk. Actimed is small, private, and running Phase 2 without a big-pharma partner. Enrollment pace and site quality in obesity trials during the peak GLP-1 era are competitive, since every patient is being courted by multiple sponsors. Commercial and regulatory risk. GLP-1-induced sarcopenia is not a recognized FDA indication category. Actimed would likely need to negotiate a functional-endpoint label with FDA or pursue a broader 'muscle preservation in weight loss' claim, both of which lengthen and complicate the pivotal design. Payer question: whether formularies will cover a chronic beta-blocker layered onto a $1,000-a-month GLP-1. Without a hard functional benefit or a clear responder subgroup, formulary access is uncertain even in a positive trial scenario. IP risk. The racemate is off-patent; Actimed's exclusivity rests on the enantiomer, salt form, and any method-of-use claims, none of which have been quantified in the public record.

Worth tracking, not a position. The muscle-preservation-on-GLP-1 problem is real, and every serious obesity company has an internal program on it. Lilly's acquisition of Versanis for up to $1.925B in 2023 to get bimagrumab, an activin type II receptor antibody, priced this thesis explicitly [9]. Bimagrumab monotherapy in adults with T2D and obesity produced roughly a 20.5% reduction in total body fat mass and a gain in lean mass over 48 weeks in the Phase 2 Heymsfield study [10], and the more recent BELIEVE combination trial with semaglutide reports substantial lean preservation on the combination. Regeneron's trevogrumab (anti-myostatin) in the COURAGE Phase 2b, with or without garetosmab (anti-activin A), preserved roughly 50-80% of the lean mass otherwise lost on semaglutide alone [11]. Lilly also has an internal myostatin-class program in its pipeline that creates intra-company competition for the bimagrumab asset. ACM-001.1 is the cheap, oral, small-molecule bet against a category dominated by expensive injectable biologics. The specific signal to watch in PROACT: LBM preservation versus placebo in the range of 1-2 kg (which would be roughly on par with the smaller effect sizes reported for the biologic competitors on the LBM axis) without meaningful reduction in total weight loss. Anything less and the payer story does not hold. Any hint of blunted fat loss is a program-killer. Check back when Actimed publishes PROACT interim data or announces a strategic partnership. The most plausible commercial path is a licensing deal to a mid-cap metabolic pharma before Phase 3, because Actimed almost certainly lacks the capital for a pivotal trial with functional endpoints. Track via Actimed press releases and the Journal of Cachexia, Sarcopenia and Muscle, where Coats and colleagues are the recurring authors on this program.